Dendritic cell vaccines for cancer therapy

Cancer Treatment Reviews

Volumn 27, Issue 4, 2001, Pages 247-255

  Sprinzl, G M ^a   Kacani, L ^b   Schrott Fischer, A ^a   Romani, N ^c   Thumfart, W F ^a  

^a Department of Otorhinolaryngology Head and Neck Surgery ^*  (Austria)

^b Institute of Hygiene and Social Medicine   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Cancer therapy; Dendritic cells; Immunologic adjuvants; Immunotherapy; Tumour specific vaccine; Vaccination

Indexed keywords

CANCER VACCINE; CYTOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; PEPTIDE DERIVATIVE; TUMOR ANTIGEN; TUMOR VACCINE;

ANTIGEN PRESENTING CELL; ARTICLE; CANCER; CANCER CELL; CANCER IMMUNOLOGY; CELL FUNCTION; CELL KILLING; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSTIMULATION; IMMUNOTHERAPY; REVIEW; SOLID TUMOR; TUMOR IMMUNITY; VACCINATION;

EID: 0034855107     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.2001.0221     Document Type: Article

References (60)

1. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
2. Vaccination of melanoma patients with pep
3. Failure of cancer vaccines: The significant limitations of this approach to immunotherapy
4. Cancer antigens: Immune recognition of self and altered self
5. Cancer vaccines
6. Therapeutic vaccination for cancer
7. Immunomodulation of cancer: Potential use of selectively replicating agents
8. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
9. Phase 1 study in patients with metastatic melanoma of immunisation with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100
10. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells
11. Report from the International Union Against Cancer (UICC) Tumour Biology Committee: UICC workshop on the use of dendritic cells in cancer clinical trials
12. New perspectives on immunobiology and immunotherapy of melanoma
13. Dendritic cells in cancer immunotherapy
14. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells
15. Regression of human metastatic renal cell carcinoma after vaccination with tumour cell-dendritic cell hybrids
16. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease
17. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study
18. Tolerance, danger, and the extended family
19. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro
20. The distinct surface of human blood dendritic cells, as observed after an improved isolation method
21. Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium
22. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability
23. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumour necrosis factor alpha
24. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions
25. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells
26. A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment
27. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
28. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application
29. Eradication of established murine tumours using a novel cell-free vaccine: Dendritic cell-derived exosomes
30. Dendritic cells: At the clinical crossroads
31. Immunobiology of dendritic cells
32. Where have all the T cells gone? Mechanisms of immune evasion by tumours
33. The Fas counterattack in vivo: Apoptotic depletion of tumour-in filtrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma
34. CTL granules: Evolution of vesicles essential for combating virus infections
35. Controlling HIV pathogenesis: The role of the noncytotoxic anti-HIV response of CD8+ T cells
36. Tumour infiltrating lymphocytes in relation to tumour angiogenesis, apoptosis and prognosis in patients with large cell lung carcinoma
37. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
38. Consequences of cell death: Exposure to necrotic tumour cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
39. Clinical trials of antibody therapy
40. Rituximab (anti-CD20) therapy of B-cell lymphomas: Direct complement killing is superior to cellular effector mechanisms
41. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: Enhancement by cotransfection of genes encoding the Th1-biasing and IFN-alpha
42. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
43. High efficiency adenovirus-mediated gene transfer to human dendritic cells
44. Human tumour and dendritic cell hybrids generated by electrofusion: Potential for cancer vaccines
45. Immunotherapy with dendritic cells directed against tumour antigens shared with normal host cells results in severe autoimmune disease
46. Papillomaviruses causing cancer: Evasion from host-cell control in early events in carcinogenesis
47. Dendritic cells pulsed with CEA peptide induce CEA-specific CTL with restricted TCR repertoire
48. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides
49. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide
50. Molecular classification of cutaneous malignant melanoma by gene expression profiling
51. Genomic views of the immune system
52. The 17-1A antigen is expressed on primary, metastatic and disseminated non-small cell lung carcinoma cells
53. Detection and clinical relevance of micrometastatic cancer cells
54. Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumour cells in lymph node metastases
55. Genomic analysis of metastasis reveals an essential role for RhoC
56. Detection and clinical importance of micrometastatic disease
57. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer
58. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites
59. Immunity 2000
60. Dendritic cells and the control of immunity